- Report
- August 2022
United States
From €1766EUR$1,940USD£1,500GBP
- Report
- August 2022
United States
From €1766EUR$1,940USD£1,500GBP
- Report
- November 2020
- 199 Pages
Global
€4096EUR$4,500USD£3,479GBP
- Report
- August 2024
- 82 Pages
Global
From €3500EUR$4,119USD£3,077GBP
- Report
- December 2022
- 289 Pages
Global
From €2275EUR$2,500USD£1,933GBP
- Report
- October 2022
- 286 Pages
Global
From €2275EUR$2,500USD£1,933GBP
- Report
- May 2022
- 103 Pages
Global
From €1820EUR$2,000USD£1,546GBP
- Report
- May 2022
- 230 Pages
Global
From €2275EUR$2,500USD£1,933GBP
- Report
- August 2024
- 295 Pages
Global
From €1692EUR$1,859USD£1,437GBP
€2416EUR$2,655USD£2,052GBP
- Report
- July 2024
- 216 Pages
Global
From €1692EUR$1,859USD£1,437GBP
€2416EUR$2,655USD£2,052GBP
The Age Related Macular Degeneration (AMD) Drug market is a subset of the Optical Disorders Drugs market. AMD is a degenerative eye condition that affects the macula, the part of the eye responsible for central vision. AMD is the leading cause of vision loss in people over the age of 50. Treatment options for AMD include drugs, laser therapy, and surgery.
Drugs used to treat AMD include anti-VEGF drugs, which block the growth of abnormal blood vessels in the eye, and corticosteroids, which reduce inflammation. These drugs are typically administered via intravitreal injections.
The AMD Drug market is highly competitive, with a number of companies offering treatments. These include Regeneron Pharmaceuticals, Novartis, Allergan, and Roche. Show Less Read more
